Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy?
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
AbstractDespite significant medical advances, glioblastoma multiforme (GBM) remains a formidable therapeutic challenge. Advent of targeted capture sequencing and patients-derived organoid cultures may hold the key to scientifically sound individualized treatment approaches. We report on our initial experience of using the combination of these two technologies to create a tailored approach of systemic therapies for a patient with GBM, which challenges the conventional treatment paradigm, as well as specifically highlighting the complexities of such an approach and the potential for a more favorable treatment outcome.
Acceptance Date20/04/2020
All Author(s) ListHerbert HF LOONG, Alissa M WONG, Danny TM CHAN, Maggie SH CHEUNG, Chit CHOW, Xiaofan DING, Aden KY CHAN, Paul A JOHNSTON, James YW LAU, Wai Sang POON, Nathalie WONG
Journal nameJournal of Clinical Neuroscience
Volume Number78
PublisherElsevier Ltd
Pages400 - 402
LanguagesEnglish-United Kingdom
KeywordsCancer organoid, Glioblastoma, Targeted therapy, Capture sequencing

Last updated on 2021-17-09 at 00:21